

**Pacira BioSciences**  
**Investor Relations FAQs on COVID-19**  
**March 24, 2020**

**1. What areas of the business may be impacted by COVID-19?**

The COVID-19 pandemic is driving a number changes in the current business environment. It is impossible to predict the duration and extent of these changes, including:

- The postponement or cancellation of elective procedures.
- The extent of shifting procedures to the outpatient or ambulatory settings.
- Broadened government mandates of social distancing and reduced trips to healthcare providers.
- Cancellations of medical meetings and data presentations.
- Reprioritization of FDA resources.
- Roughly 60% of EXPAREL procedures are already taking place outside of the hospital inpatient setting; however, some states have mandated that ambulatory surgery centers and hospital outpatient departments also cancel elective surgical procedures, making it unclear the extent to which these sites of care will continue to perform elective, non-urgent procedures during the coming weeks in light of COVID-19.
- Much of our growth has been driven by the use of EXPAREL in procedures that we do not believe will be delayed, such as cesarean section and trauma surgery, as well as certain gynecologic oncology, breast cancer, cardiovascular, and spine cases.
- We will provide additional details in our first quarter earnings disclosures as more data become available.

**2. What is the breakdown of reimbursement for EXPAREL between government and commercial payers?**

Reimbursement for our products is approximately 50% covered by government programs and 50% covered by commercial payers.

**3. What is the impact of COVID-19 to the EXPAREL and iovera<sup>®</sup> supply chains?**

Pacira continues to have normal supply levels for EXPAREL and iovera<sup>®</sup>; our manufacturing operations are up and running in our San Diego and Swindon facilities. Neither facility has been affected to date. We are monitoring our supply chain closely.

**4. How many months of inventory is on hand?**

Generally, we target having six months of prospective inventory on hand. We do not disclose months of inventory on hand in real-time.

**5. Have you experienced any impact from China suppliers?**

We do not have exposure to China suppliers and have not learned of any supply interruptions or late deliveries from any of our suppliers.

**6. Do you have any exposure in Italy?**

We do not have any manufacturing or supply exposure in Italy.

**7. Has COVID-19 impacted or halted your ongoing clinical trials for EXPAREL?**

To date, none of our studies have been halted. Each site has unique rules for elective surgery, so some sites are continuing to enroll patients and some have stopped. Initiating new sites and closing out sites may prove challenging as there are a growing number of restrictions with respect to access to the hospitals.

- We expect this may potentially impact our timelines for completing enrollment in our Phase 4 FUSION spine study and our Phase 3 lower extremity nerve block STRIDE study, as well as the closing out our Phase 4 CHOICE study.
- We may also delay the launch of our Phase 1 study of a DepoFoam-based local anesthetic administered as a subarachnoid, or spinal block, but the extent of such delays is still not clear.
- Importantly, our Phase 3 pediatric label expansion study was completed last year and we are in the process of preparing our supplemental New Drug Application for submission to the FDA.

**8. Do you anticipate a delay in submitting your supplementary New Drug Application (sNDA) to U.S. Food and Drug Administration (FDA) seeking the expansion of the EXPAREL label to include pediatric patients?**

We do not anticipate an impact on the timing of our submission of the pediatric sNDA. We cannot predict what, if any, impact there will be on the FDA's ability to review the sNDA within the Prescription Drug User Fee Act, or PDUFA, timelines.

**9. What is the impact on the overall Pacira workforce?**

Our activities supporting the manufacture of EXPAREL are deemed essential in the states in which we operate and are fully operational. Most of our office- and lab-based colleagues are primarily working from home and performing their normal job responsibilities.

**10. What is the impact on the Pacira salesforce?**

In many markets, the Pacira sales team is working from home and providing customer product and reimbursement support using digital tools. The Pacira sales team is no longer making sales calls to hospitals.

*Forward-Looking Statements*

*Any statements in this press release about the company's future expectations, plans, outlook, projections and prospects, and other statements containing the words "believes," "anticipates," "plans," "estimates," "expects," "intends," "may," "will," "would," "could," "can" and similar expressions, constitute forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including risks relating to: the impact of the COVID-19 pandemic on surgeries, our manufacturing and supply chain and the economy at large; the success of the company's sales and manufacturing efforts in support of the commercialization of EXPAREL; the rate and degree of market acceptance of EXPAREL; the size and growth of the potential markets for EXPAREL and the company's ability to serve those markets; the company's plans to expand the use of EXPAREL to additional indications and opportunities, and the timing and success of any related clinical trials; the ability to realize anticipated benefits and synergies from the acquisition of MyoScience; the ability to successfully integrate iovera° and any other future acquisitions into the company's existing business; the*

*commercial success of iovera® and other factors discussed in the “Risk Factors” of the company’s most recent Annual Report on Form 10-K and in other filings that the company periodically makes with the SEC. In addition, the forward-looking statements included in this press release represent the company’s views as of the date of this press release. Important factors could cause actual results to differ materially from those indicated or implied by forward-looking statements, and as such the company anticipates that subsequent events and developments will cause its views to change. However, while the company may elect to update these forward-looking statements at some point in the future, it specifically disclaims any obligation to do so. These forward-looking statements should not be relied upon as representing the company’s views as of any date subsequent to the date of this document.*